Industry
Biotechnology
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.
Loading...
Open
2.23
Mkt cap
57M
Volume
156K
High
2.28
P/E Ratio
-1.65
52-wk high
5.33
Low
2.10
Div yield
N/A
52-wk low
0.89
Portfolio Pulse from Benzinga Newsdesk
October 31, 2024 | 5:17 pm
Portfolio Pulse from Benzinga Newsdesk
October 23, 2024 | 12:11 pm
Portfolio Pulse from Benzinga Insights
October 15, 2024 | 8:30 pm
Portfolio Pulse from Benzinga Newsdesk
October 09, 2024 | 11:14 am
Portfolio Pulse from Benzinga Newsdesk
October 07, 2024 | 6:26 pm
Portfolio Pulse from Benzinga Newsdesk
October 07, 2024 | 11:16 am
Portfolio Pulse from Benzinga Newsdesk
October 01, 2024 | 10:57 am
Portfolio Pulse from Benzinga Newsdesk
September 30, 2024 | 4:24 pm
Portfolio Pulse from Benzinga Newsdesk
September 30, 2024 | 4:19 pm
Portfolio Pulse from Benzinga Insights
September 27, 2024 | 8:31 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.